ArticleInternational urology and nephrology2025

Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.

Felix Steffens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.